Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LHF-535 is an antiviral compound. It has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 9,000 | |||
5 mg | 在庫あり | ¥ 15,000 | |||
10 mg | 在庫あり | ¥ 22,500 | |||
25 mg | 在庫あり | ¥ 40,000 | |||
50 mg | 在庫あり | ¥ 66,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 16,000 |
説明 | LHF-535 is an antiviral compound. It has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively. |
In vitro | LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 inhibits Lassa GP-pseudotyped lentivirus (IC50: 0.1-0.3 nM). LHF-535 shows effective antiviral activity against a broad array of hemorrhagic fever arenaviruses [2]. |
In vivo | An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection. LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protects mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver [2]. |
分子量 | 412.52 |
分子式 | C27H28N2O2 |
CAS No. | 1450929-77-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 96.67 mg/mL (234.34 mM), Sonication is recommended.
H2O: < 0.1 mg/mL (insoluble)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LHF-535 1450929-77-7 Immunology/Inflammation Microbiology/Virology Antiviral Virus Protease inhibit Arenavirus LHF535 LHF 535 Inhibitor inhibitor